CDT Equity Inc.

CDT Equity Inc., formerly Conduit Pharmaceuticals Inc., is a data-driven pharmaceutical development company that identifies, enhances, and advances high-potential therapeutic assets. The company leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. CDT Equity focuses on clinical-stage compounds, particularly those deprioritized by larger pharmaceutical companies, that have strong supporting Phase I safety data. Through advanced co-crystallization and solid-form technologies developed at its Cambridge facilities, the company improves drug properties and extends patent life by up to 20 years. In partnership with Sarborg Limited, CDT Equity applies AI-powered signature analysis to rapidly identify new therapeutic applications and combinations for existing compounds. The company's pipeline includes candidates targeting autoimmune disorders, idiopathic male infertility, oncology, dermatology, rare disease, and animal health. Ongoing in vitro and in vivo studies, guided by AI insights, support licensing and commercialization partnerships. CDT Equity seeks an exit through third-party license deals following successful in vitro and in vivo pre-clinical trials, entering into agreements with third parties for further development, FDA approval, commercialization, and marketing of its assets. The company operates with a lean, asset-agnostic model, prioritizing speed, adaptability, and capital efficiency, and avoids the cost burden of early and late-stage clinical trials. Its current pipeline includes candidates targeting inflammatory and autoimmune disorders, idiopathic male infertility, dermatology, and animal health. The intellectual property portfolio includes pending patent applications in several international jurisdictions describing a solid-form compound, including the AZD1656 Cocrystal (a HK-4 Glucokinase Activator). The company's pipeline research includes compounds identified as promising alternatives to existing clinical assets marketed by large pharmaceutical companies, presenting opportunities to develop further intellectual property positions through solid-form technology.